Record the offer with its date
SuperHealthy Rx's promotional page lists semaglutide at $85 monthly and tirzepatide at $135. It continued to show Labor Day sale wording when we checked it on October 5, 2026. A saved checkout confirmation is more useful than assuming a seasonal promotion will remain unchanged. Verify the amount and period actually offered to you.
The bundle and the next order
The page describes medical review, compounded medication and shipping together, without a separate membership fee. It presents automatic refills as optional. Ask where the selected refill setting appears and what process applies before another prescription or shipment is issued. An advertised refill option is not a substitute for understanding the clinical review.
Write down the responsible organizations
The service refers to an MD Integrations clinician network and U.S. licensed pharmacies. Obtain the specific prescriber and pharmacy details for your own order rather than relying on the network description. Those names help route a question about the medicine, its label or the delivery to the right place.
Use the actual instructions
The reviewed products are compounded and are not FDA-approved. Ask the clinician why the proposed preparation fits the medical need and ask the pharmacist to resolve product-instruction questions. Keep the confirmed instructions accessible; a provider advertisement is not a practical substitute for the directions accompanying a prescription.
SuperHealthy is promotional #2 by publisher selection. Links may earn compensation. We have not purchased its medicines, tested its follow-up or inspected dispensing operations. The notebook approach is limited to public offer information and the details a reader may need to confirm and retain before relying on the arrangement.
Source notes
Checked October 5, 2026. Provider pages document advertised terms. Study summaries identify the scope of our review.
- SuperHealthy Rx — current GLP-1 promotionProvider offer
- FDA — compounding questions and answersRegulatory context
- FDA — unapproved GLP-1 drug concernsSafety information